Recent results from a pilot trial testing the ‘Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19’ (IMPACT-SIRIO 5; NCT04941105) demonstrate a survival benefit among adult patients.27 It is conceivable that such therapies will be trialed in other critically ill cohorts including sepsis and acute respiratory distress syndrome. This evidence concerns the gene PCSK9 and Sepsis.